涉316种常用药品！

Core Viewpoint - The new round of national centralized procurement for pharmaceuticals has resulted in proposed selection outcomes for 4,163 products from 1,020 companies, covering 316 commonly used drugs [1] Group 1: Procurement Details - The procurement includes drugs across 26 therapeutic areas such as anti-infection, anti-tumor, blood sugar reduction, blood pressure reduction, blood lipid reduction, nervous system, respiratory system, and digestive system [1] - The demand matching rate for the reported brands by medical institutions reached 88% [1] - The majority of the previously selected products continue to be selected, with a selection rate of 98% [1] Group 2: Implementation and Coordination - This procurement marks the first nationwide unified continuation of centralized procurement for chemical drugs organized by the state [1] - The procurement is led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces, with participation from all provinces to ensure standardized procurement rules [1] - The results of this procurement are expected to be implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028 [1]